DALLAS and SAN DIEGO, Oct. 7, 2025 /PRNewswire/ — Koya Medical (“Koya”), an emerging medtech innovator advancing patient-centered solutions in vascular health, announced today that CEO Andy Doraiswamy will participate in The MedTech Conference 2025, taking place October 5–8 in San Diego….
Other News
ACORAI Presents Positive Results in 1,600-Patient CAPTURE-HF Study for its AI-Powered Non-Invasive Multi-Sensor Platform for Improved Heart Failure Patient Management
MINNEAPOLIS, Oct. 6, 2025 /PRNewswire/ — Acorai, a clinical-stage company pioneering non-invasive hemodynamic monitoring for heart failure management, this week announced topline results from the 1,600-patient CAPTURE-HF study (Machine-Learning Estimation of Pulmonary Capillary Wedge and…
Vascular Health joins United Vein and Vascular Centers to Expand Access to Advanced Vascular Care
TAMPA, Fla., Oct. 6, 2025 /PRNewswire/ — United Vein & Vascular Centers (UVVC), a national leader in comprehensive vein and vascular care, is proud to welcome Vascular Health, a New Jersey based vascular practice with a proven track record in treating peripheral artery disease (PAD),…
Remedy Robotics Debuts Pioneering Endovascular Surgical Robotic System and Completes World’s First Fully Remote Neurointerventional Procedures
Groundbreaking remotely operable robotic system to transform intervention for stroke and cardiovascular disease, while radically expanding access to care for patients around the world. SAN FRANCISCO, Oct. 6, 2025 /PRNewswire/ — Remedy Robotics, Inc., a leading medical technology company,…
AtaCor Medical Secures $75M Financing to Support the Pivotal U.S. Study of its Extravascular ICD (EV-ICD) System
The novel design of AtaCor’s Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies with no hardware placed in the heart or vasculature SAN CLEMENTE, Calif., Oct. 6, 2025 /PRNewswire/ — AtaCor Medical, Inc., a privately-held medical device company…
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
Med Tech segment delivers fourth consecutive quarter of over 20% revenue growth Reported Adjusted EBITDA of $2.2 million compared to ($0.2) million in the prior year Continues to expect to be cash flow positive for the full fiscal year 2026 Raised full year FY 2026 guidance for net sales, Med […]
Medtronic receives CE Mark for Penditure™ Left Atrial Appendage (LAA) Exclusion System, ushering in a new era of left atrial appendage management in Europe as it surpasses 10,000 Penditure Devices Sold Globally
Medtronic plc, a global leader in healthcare technology, today announced its Penditure™ Left Atrial Appendage (LAA) Exclusion System has officially received CE Mark approval and will be launched in Europe at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting from October 8-11 in Copenhagen, Denmark. The Penditure device recently […]
Positron Corporation Enters Industry Partnership Agreement with MedAxiom
Buffalo, NY, Oct. 02, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging technology company specializing in PET and PET-CT imaging systems and clinical services is pleased to announce a partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions.
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK9 Inhibitor to Demonstrate Significant Reduction of Cardiovascular Events as Both Primary…
Groundbreaking Therapy for Advanced Heart Failure: Repairon Completes Series A Financing to Expand the Clinical Development of Its Regenerative Heart Therapy
GÖTTINGEN, Germany, Oct. 2, 2025 /PRNewswire/ — German biotech company Repairon GmbH announced the completion of a Series A round of financing that will enable further clinical development of its groundbreaking regenerative heart failure therapy. The therapy repairs cardiac function and…



